
Supplements and Featured Publications
- Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin
- Volume 21
- Issue 11 Suppl
eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS
eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS
Evaluated renin-angiotensin-aldosterone system (RAAS) inhibitor drugs and their maximum doses, listed in descending order of observed frequency at index: lisinopril, 40 mg; losartan, 100 mg; valsartan, 320 mg; benazepril, 80 mg; olmesartan, 40 mg; enalapril, 40 mg; spironolactone, 200 mg; irbesartan, 300 mg; ramipril, 10 mg; quinapril, 80 mg; telmisartan, 80 mg; candesartan, 32 mg; captopril, 450 mg; fosinopril, 40 mg; trandolapril, 8 mg; moexipril, 30 mg; aliskiren, 300 mg; eplerenone, 100 mg; perindopril, 8 mg; eprosartan, 800 mg; azilsartan, 80 mg.
Aliskiren/valsartan formulated 150 mg-160 mg (a partial dose of each of 2 RAAS inhibitor drugs) was considered a partial dose (submaximum).
Articles in this issue
about 10 years ago
eAPPENDIX 3. ADVERSE OUTCOME DEFINITIONSabout 10 years ago
eAPPENDIX 1. ICD-9 CODES USED FOR CLASSIFICATION OF COMORBIDITIESNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.